ESMO 2026 | The clinical significance of the INTerpath-001 and STARBOARD in melanoma
Sapna Patel
• 23 Oct 2026
Sapna Patel, MD, Colorado Cancer Center, Aurora, CO, describes the potential impact of recent melanoma trials on future clinical practice guidelines, noting that while the INTerpath-001 trial (NCT05933577) is awaiting overall survival maturity, the STARBOARD trial (NCT04657991) have reported positive Phase III results and may soon be reviewed for regulatory approval. These developments may lead to updates in guidelines such as the ESMO clinical practice guidelines in the future. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
